Muscarinic receptors: their roles in disorders of the central nervous system and potential as therapeutic targets.
paper
Cited
Public
Unavailable
- Authors
- Scarr, Elizabeth
- Year
- 2012
- Journal
- CNS neuroscience & therapeutics
- PMID
- 22070219
- DOI
- 10.1111/j.1755-5949.2011.00249.x
- PMCID
- PMC6493542
Phylogenetically, acetylcholine is an ancient neurochemical. Therefore, it is not surprising that cholinergic neurons project extensively throughout the central nervous system, innervating a wide range of structures within the brain. In fact, acetylcholine is involved in processes that underpin some of our most basic central functions. Both muscarinic and nicotinic receptor families, which mediate cholinergic transmission, have been implicated in the pathophysiology of psychiatric and neurological disorders. The question that remains to be definitively answered is whether or not these receptors are viable targets for the development of future therapeutic agents.
No figures extracted from this document.
No chunks β full text not yet ingested.
No entities extracted from this document yet.
No uploaded files.
Not in any collection.
No citations found.
In this knowledge base
| Title | Year | PMID |
|---|---|---|
| Genetic and neurophysiological correlates of the age of onset of alcohol use disorders in adolescents and young adults. | 2013 | 23963516 |
External
| Title | Authors | Journal | Year | Link |
|---|---|---|---|---|
| Discovery of VU6025733 (AG06827): A Highly Selective, Orally Bioavailable, and Structurally Distinct M<sub>4</sub> Muscarinic Acetylcholine Receptor Positive Allosteric Modulator (PAM) with Robust <i>In Vivo</i> Efficacy. | Gregro AR et al. | β | 2026 | β |
| Developing muscarinic receptor M1 classification models utilizing transfer learning and generative AI techniques. | Dey S et al. | β | 2025 | β |
| Efficacy and Safety of KarXT (Xanomeline-Trospium; Cobenfyβ’) in Schizophrenia: A Systematic and Meta-Analysis Review of Randomized Controlled Trials. | Azargoonjahromi A et al. | β | 2025 | β |
| Lipids shape brain function through ion channel and receptor modulations: physiological mechanisms and clinical perspectives. | Incontro S et al. | β | 2025 | β |
| Long COVID - a critical disruption of cholinergic neurotransmission? | Leitzke M et al. | β | 2025 | β |
| Novel Drug Targets for Neurodegenerative Diseases of Elderly People to Develop Effective Therapeutics: A Comprehensive Analysis. | Biswas P et al. | β | 2025 | β |
| Role of the Central Cholinergic Nervous System in Motor and Non-Motor Symptoms of Parkinson's Disease. | Tian SY et al. | β | 2025 | β |
| A preliminary study of the effects of an antimuscarinic agent on anxious behaviors and white matter microarchitecture in nonhuman primates. | Aggarwal N et al. | β | 2024 | β |
| Central cholinergic transmission affects the compulsive-like behavior of mice in marble-burying test. | Patel C et al. | β | 2024 | β |
| Co-stimulation of muscarinic M1 and M4 acetylcholine receptors prevents later cocaine reinforcement in male and female mice, but not place-conditioning. | Balakrishnan AS et al. | β | 2024 | β |
| Effects of DDT and DDE on placental cholinergic receptors. | Uyar R et al. | β | 2024 | β |
| IUPHAR Review on muscarinic M1 and M4 receptors as drug treatment targets relevant to the molecular pathology of schizophrenia. | Dean B | β | 2024 | β |
| Lower levels of kainate receptors, but not AMPA or NMDA receptors, in Brodmann's area (BA) 9, but not BA 10, from a subgroup of people with schizophrenia who have a marked deficit in cortical muscarinic M1 receptors. | Snelleksz M et al. | β | 2024 | β |
| PET imaging of M4 muscarinic acetylcholine receptors in rhesus macaques using [<sup>11</sup>C]MK-6884: Quantification with kinetic modeling and receptor occupancy by CVL-231 (emraclidine), a novel positive allosteric modulator. | Belov V et al. | β | 2024 | β |
| Cognitive effects of individual anticholinergic drugs: a systematic review and meta-analysis. | Naseri A et al. | β | 2023 | β |
| Compulsive-like Behaviors in Amyloid-Ξ² 1-42-Induced Alzheimer's Disease in Mice Are Associated With Hippocampo-cortical Neural Circuit Dysfunction. | Shivakumar AB et al. | β | 2023 | β |
| EEG changes as an indication of central nervous system involvement following cyclopentolate 1% eye drops; a randomized placebo-controlled pilot study in a pediatric population. | van Minderhout HM et al. | β | 2023 | β |
| Effect of Clemastine on Neurophysiological Outcomes in an Ovine Model of Neonatal Hypoxic-Ischemic Encephalopathy. | Mike JK et al. | β | 2023 | β |
| G protein-coupled receptors in neurodegenerative diseases and psychiatric disorders. | Wong TS et al. | β | 2023 | β |
| Hippocampal cholinergic receptors and the mTOR participation in fear-motivated inhibitory avoidance extinction memory. | Rosa J et al. | β | 2023 | β |
| Is the post-COVID-19 syndrome a severe impairment of acetylcholine-orchestrated neuromodulation that responds to nicotine administration? | Leitzke M | β | 2023 | β |
| Lower levels of cortical [<sup>3</sup>H]pirenzepine binding to postmortem tissue defines a sub-group of older people with schizophrenia with less severe cognitive deficits. | Dean B et al. | β | 2023 | β |
| Muscarinic M1 and M4 receptor agonists for schizophrenia: promising candidates for the therapeutic arsenal. | Dean B | β | 2023 | β |
| Neurotransmitter systems in the etiology of major neurological disorders: Emerging insights and therapeutic implications. | Nimgampalle M et al. | β | 2023 | β |
| The M1 muscarinic acetylcholine receptor regulates the surface expression of the AMPA receptor subunit GluA2 via PICK1. | Zhu Z et al. | β | 2023 | β |
| Abuse of tropicamide eye drops: review of clinical data. | Bellman V et al. | β | 2022 | β |
| Allosteric Modulation of Muscarinic Receptors by Cholesterol, Neurosteroids and Neuroactive Steroids. | Szczurowska E et al. | β | 2022 | β |
| Anticholinergics: A potential option for preventing posttraumatic epilepsy. | Sanabria V et al. | β | 2022 | β |
| A PDE10A inhibitor CPL500036 is a novel agent modulating striatal function devoid of most neuroleptic side-effects. | Matloka M et al. | β | 2022 | β |
| Beauty of the beast: anticholinergic tropane alkaloids in therapeutics. | Shim KH et al. | β | 2022 | β |
| Design, Synthesis, and Biological Evaluation of 4,4'-Difluorobenzhydrol Carbamates as Selective M<sub>1</sub> Antagonists. | Kilian J et al. | β | 2022 | β |
| Dose-Dependency of Toxic Signs and Outcomes of Paraoxon Poisoning in Rats. | MaksimoviΔ Ε½M et al. | β | 2022 | β |
| Modulation of Muscarinic Signalling in the Central Nervous System by Steroid Hormones and Neurosteroids. | Szczurowska E et al. | β | 2022 | β |
| Normalization of impaired emotion inhibition in bipolar disorder mediated by cholinergic neurotransmission in the cingulate cortex. | Nabulsi L et al. | β | 2022 | β |
| The Pathobiology of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: The Case for Neuroglial Failure. | Renz-Polster H et al. | β | 2022 | β |
| Anticholinergic medication: Related dry mouth and effects on the salivary glands. | Arany S et al. | β | 2021 | β |
| Brain injuries can set up an epileptogenic neuronal network. | Pototskiy E et al. | β | 2021 | β |
| Control of Brain State Transitions with a Photoswitchable Muscarinic Agonist. | Barbero-Castillo A et al. | β | 2021 | β |
| Lacidipine Prevents Scopolamine-Induced Memory Impairment by Reducing Brain Oxido-nitrosative Stress in Mice. | Khurana K et al. | β | 2021 | β |
| Major surgery leads to a proinflammatory phenotype: Differential gene expression following a laparotomy. | Dobson GP et al. | β | 2021 | β |
| Muscarinic Acetylcholine Receptors in the Retina-Therapeutic Implications. | Ruan Y et al. | β | 2021 | β |
| Potential Role for Combined Subtype-Selective Targeting of M<sub>1</sub> and M<sub>3</sub> Muscarinic Receptors in Gastrointestinal and Liver Diseases. | Tolaymat M et al. | β | 2021 | β |
| A Review of the Cholinergic System and Therapeutic Approaches to Treat Brain Disorders. | Bertrand D et al. | β | 2020 | β |
| Cellular Targeting of Oligonucleotides by Conjugation with Small Molecules. | Hawner M et al. | β | 2020 | β |
| Cholinergic Dysfunction Involvement in Chronic Cerebral Hypoperfusion-Induced Impairment of Medial Septum-dCA1 Neurocircuit in Rats. | Xu Y et al. | β | 2020 | β |
| Chronic Administration of Scopolamine Increased GSK3Ξ²P9, Beta Secretase, Amyloid Beta, and Oxidative Stress in the Hippocampus of Wistar Rats. | HernΓ‘ndez-RodrΓguez M et al. | β | 2020 | β |
| Functional coupling of M<sub>1</sub> muscarinic acetylcholine receptor to GΞ±<sub>q/11</sub> in dorsolateral prefrontal cortex from patients with psychiatric disorders: a postmortem study. | Odagaki Y et al. | β | 2020 | β |
| Pharmacological Modulators of Tau Aggregation and Spreading. | Dominguez-Meijide A et al. | β | 2020 | β |
| Control of brain state transitions with light | Barbero-Castillo A et al. | β | 2019 | β |
| Genetic polymorphisms of CYP3A5, CHRM2, and ZNF498 and their association with epilepsy susceptibility: a pharmacogenetic and case-control study. | Al-Eitan LN et al. | β | 2019 | β |
| G<sub>i/o</sub>-Protein Coupled Receptors in the Aging Brain. | de Oliveira PG et al. | β | 2019 | β |
| Pharmacological and toxicological in vitro and in vivo effect of higher doses of oxime reactivators. | Hepnarova V et al. | β | 2019 | β |
| Small vessel disease to subcortical dementia: a dynamic model, which interfaces aging, cholinergic dysregulation and the neurovascular unit. | Caruso P et al. | β | 2019 | β |
| Sexually diergic hypothalamic-pituitary-adrenal axis responses to selective and non-selective muscarinic antagonists prior to cholinergic stimulation by physostigmine in rats. | Smail MA et al. | β | 2018 | β |
| Acetylcholinesterase Inhibitors and Drugs Acting on Muscarinic Receptors- Potential Crosstalk of Cholinergic Mechanisms During Pharmacological Treatment. | Soukup O et al. | β | 2017 | β |
| Antimuscarinic Use in Females With Overactive Bladder Syndrome Increases the Risk of Depressive Disorder: A 3-Year Follow-up Study. | Chung SD et al. | β | 2017 | β |
| Guarana (Paullinia cupana) ameliorates memory impairment and modulates acetylcholinesterase activity in Poloxamer-407-induced hyperlipidemia in rat brain. | Ruchel JB et al. | β | 2017 | β |
| Probing the cholinergic system to understand neurodegenerative diseases. | Renard PY et al. | β | 2017 | β |
| Anticholinergics: theoretical and clinical overview. | Nishtala PS et al. | β | 2016 | β |
| Attenuation of Compulsive-Like Behavior Through Positive Allosteric Modulation of Ξ±4Ξ²2 Nicotinic Acetylcholine Receptors in Non-Induced Compulsive-Like Mice. | Mitra S et al. | β | 2016 | β |
| Developmental neurotoxicity of polybrominated diphenyl ethers mixture de71 in Sprague-Dawley rats. | Gill S et al. | β | 2016 | β |
| G-protein coupled receptors as therapeutic targets for neurodegenerative and cerebrovascular diseases. | Guerram M et al. | β | 2016 | β |
| To quit or not: Vulnerability of women to smoking tobacco. | Park SJ et al. | β | 2016 | β |
| Anticholinergic drug burden in older people's brain - how well is it measured? | Kersten H et al. | β | 2014 | β |
| Long-term effects of maternal deprivation on cholinergic system in rat brain. | MarkoviΔ B et al. | β | 2014 | β |
| Cholinergic connectivity: it's implications for psychiatric disorders. | Scarr E et al. | β | 2013 | β |
| Genetic and neurophysiological correlates of the age of onset of alcohol use disorders in adolescents and young adults. | Chorlian DB et al. | β | 2013 | β |
| Pharmacological characterization of M1 muscarinic acetylcholine receptor-mediated Gq activation in rat cerebral cortical and hippocampal membranes. | Odagaki Y et al. | β | 2013 | β |
| Emerging opportunities for serotypes of botulinum neurotoxins. | Peng Chen Z et al. | β | 2012 | β |